Capitolis Liquid Global Markets LLC Purchases New Stake in Astrazeneca Plc $AZN

Capitolis Liquid Global Markets LLC acquired a new position in shares of Astrazeneca Plc (NYSE:AZN) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 13,900 shares of the company’s stock, valued at approximately $1,066,000.

Several other hedge funds and other institutional investors also recently modified their holdings of AZN. Cibc World Market Inc. raised its stake in Astrazeneca by 21.5% during the third quarter. Cibc World Market Inc. now owns 64,421 shares of the company’s stock valued at $4,942,000 after buying an additional 11,398 shares in the last quarter. TD Asset Management Inc grew its position in shares of Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after acquiring an additional 181,273 shares in the last quarter. Y Intercept Hong Kong Ltd increased its holdings in shares of Astrazeneca by 111.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 66,643 shares of the company’s stock valued at $5,113,000 after acquiring an additional 35,148 shares during the last quarter. AMG National Trust Bank increased its holdings in shares of Astrazeneca by 20.4% in the 3rd quarter. AMG National Trust Bank now owns 42,983 shares of the company’s stock valued at $3,298,000 after acquiring an additional 7,289 shares during the last quarter. Finally, Oxbow Advisors LLC raised its position in shares of Astrazeneca by 96.2% during the 3rd quarter. Oxbow Advisors LLC now owns 77,594 shares of the company’s stock valued at $5,953,000 after acquiring an additional 38,043 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

Shares of AZN opened at $190.20 on Monday. Astrazeneca Plc has a 12 month low of $122.48 and a 12 month high of $212.71. The company has a quick ratio of 0.72, a current ratio of 0.94 and a debt-to-equity ratio of 0.51. The firm has a market cap of $294.98 billion, a P/E ratio of 32.77, a P/E/G ratio of 1.43 and a beta of 0.32.

Astrazeneca Dividend Announcement

The company also recently declared a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be given a dividend of $1.595 per share. The ex-dividend date is Friday, February 20th. This represents a dividend yield of 156.0%. Astrazeneca’s dividend payout ratio is currently 66.26%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Guggenheim restated a “buy” rating on shares of Astrazeneca in a research note on Wednesday, December 3rd. Wall Street Zen cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a report on Thursday. HSBC restated a “buy” rating and issued a $108.00 price target on shares of Astrazeneca in a research report on Wednesday, December 10th. Citigroup initiated coverage on shares of Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Finally, Barclays reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Tuesday, January 6th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Astrazeneca currently has a consensus rating of “Moderate Buy” and an average target price of $95.75.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.